NVDA
NVIDIA
-- 144.470 TSLA
Tesla
-- 410.440 CRNC
Cerence
-- 19.330 PLTR
Palantir
-- 79.890 MSTR
MicroStrategy
-- 339.660 
$Tonix Pharmaceuticals (TNXP.US)$ I think there are some fac...
There seems to be some positive factors.
Yesterday, the FDA accepted a new drug. If approved by the FDA in 2025, TNX-102 SL will be a new drug for fibromyalgia for the first time in over 15 years.
Tonix announced that the first patient in the Phase 2 catalyst study for TNX-1300 for cocaine addiction treatment was enrolled in August 2024. CATALYST is a Phase 2 single-blind, placebo-controlled proof-of-concept study targeting patients appearing in the emergency department. Topline results are expected in the first half of 2025.
In September 2024, at the MHSRS conference of the Department of Defense, at the World Vaccine Conference held in Barcelona, Spain in October 2024, Tonix announced new data on the potential mpox vaccine TNX-801. This indicates that even at high doses in immunocompromised animals, there is evidence of tolerability and no evidence of blood or tissue spread. TNX-801 is a weak live virus vaccine based on synthetic horsepox, which has been shown to provide immunoprotection against monkeypox challenge with a single dose. After a single dose, TNX-801 prevented clinical disease and lesions, and following lethal challenge by Clade Ia monkeypox, reduced shedding of Oreola and lung in non-human primates. These findings are consistent with the induction of mucosal immunity by TNX-801 and suggest that TNX-801 has the ability to block forward transmission.
Yesterday, the FDA accepted a new drug. If approved by the FDA in 2025, TNX-102 SL will be a new drug for fibromyalgia for the first time in over 15 years.
Tonix announced that the first patient in the Phase 2 catalyst study for TNX-1300 for cocaine addiction treatment was enrolled in August 2024. CATALYST is a Phase 2 single-blind, placebo-controlled proof-of-concept study targeting patients appearing in the emergency department. Topline results are expected in the first half of 2025.
In September 2024, at the MHSRS conference of the Department of Defense, at the World Vaccine Conference held in Barcelona, Spain in October 2024, Tonix announced new data on the potential mpox vaccine TNX-801. This indicates that even at high doses in immunocompromised animals, there is evidence of tolerability and no evidence of blood or tissue spread. TNX-801 is a weak live virus vaccine based on synthetic horsepox, which has been shown to provide immunoprotection against monkeypox challenge with a single dose. After a single dose, TNX-801 prevented clinical disease and lesions, and following lethal challenge by Clade Ia monkeypox, reduced shedding of Oreola and lung in non-human primates. These findings are consistent with the induction of mucosal immunity by TNX-801 and suggest that TNX-801 has the ability to block forward transmission.
With such good news, please go over $1...
There is a high likelihood of a stock consolidation, so I will sell the moment it happens.
I have been holding since 0.19 two months ago, so please.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment